Abstract
The effect of Z-100, an immunomodulatory arabinomannan extracted fromMycobacterium tuberculosis, on cecal ligation and puncture (CLP)-induced sepsis in mice bearing Meth-A fibrosarcoma was investigated. When normal BALB/c mice were subjected to the CLP procedure, their mortality rate was 17%. On the other hand, an increased mortality was observed in tumor-bearing mice subjected to CLP 10 days after tumor inoculation, and then all mice died when tumor- bearing mice were subjected to CLP 20 days after tumor inoculation. However, the increased percent mortality was decreased by 50% when these mice were injected intraperitoneally with a 10 mg/kg dose of Z-100. When splenocytes (5 × 107 cells), obtained from Meth-A tumor-bearing mice 20 days after tumor inoculation, were transferred intravenously to normal mice (recipient mice), mortality of these recipient mice were increased by 62% as compared with that of the control (22%). However, no increased mortality (25%) was observed in recipient mice which were transferred with splenocytes from tumor-bearing mice injected intraperitoneally with Z-100 (10 mg/kg). In addition, suppressor cell activity was demonstrated in splenocytes from Meth-A tumor-bearing mice at 20 days after tumor inoculation using one-way mixed lymphocyte reaction. However, the suppressor cell activity was significantly decreased by the intraperitoneal administration of a 10 mg/kg dose of Z-100 (p<0.01). The increase of mortality in recipient mice by adoptive transfer of mononuclear cells (MNCs) from tumor-bearing mice was not detected when these MNCs were treated with anti-Thy 1.2 monoclonal antibody (mAb), anti-Lyt 2.2 mAb or anti-CD11b mAb, but an increase was seen with anti-Lyt 1.2 mAb or anti-immunoglobulin antiserum treated MNCs.
These results suggest that the suppressor cells affect the mortality of CLP-induced sepsis and Z-100 may have a therapeutic activity against opportunistic infections in immunocompromised hosts through the regulation of suppressor T-cells.
Similar content being viewed by others
Abbreviations
- CLP:
-
cecal ligation and puncture
- MLR:
-
mixed lymphocyte reaction
- MNCs:
-
mononuclear cells
- mAb:
-
monoclonal antibody
- Ig:
-
immunoglobulin
References
Kuramochi S, Kameyama K, Hiraoka N, Hosoda Y, Kumai K, Ishibiki K: Evaluation of the importance of infection as cause of death in patients with malignancy: An analysis of autopsy cases. Jpn J cancer Chemother 1992; 19: 161–166
Roth JA: Tumor induced immunosuppression. Surg Gynecol Obstet 1983; 156: 233–240
Ishida N: Isolation of factors responsible for the immunosuppression found in tumor-bearing animals. Yakugaku Zasshi 1985; 105: 91–108
Kobatake H, Suekane T, Murakami Y, Niwa S, Okahira A, Kushida H: Studies on hot water extract ofMycobacterium tuberculosis. I. Structural analyses of polysaccharides. Yakugaku Zasshi 1981; 101: 713–722
Satoh H: Antitumor activity of an extract from tubercle bacilli of human type (Maruyama vaccine, or SSM) on ascites hepatomas in rats. Cancer Chemother 1978; 5: 545–548.
Suzuki F, Brutkiewicz RR, Pollard RB: Importance of Lyt 1+ T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type tubercle bacilli. J Natl Cancer Inst 1986; 77: 441–447
Sasaki H, Schmitt D, Hayashi Y, Pollard RB, Suzuki F: Induction of interleukin 3 and tumor resistance by SSM, a cancer immunotherapeutic agent extracted fromMycobacterium tuberculosis. Cancer Res 1990; 50: 4032–4037
Pollard RB, Schmitt DA, Sasaki H, Hayashi Y, Suzuki F: Release of a mitogenic factor by splenic Lyt 1+ T-cells from mice treated with SSM, an immunomodulator extracted from human type tubercle bacilli. Anticancer Res 1990; 10: 285–290
Hayashi Y, Ebina T, Suzuki F, Ishida N: Interferon inducing activity of an immunotherapeutic anticancer agent, SSM, prepared fromMycobacterium tuberculosis strain Aoyama B. Microbiol Immunol 1981; 25: 305–316
Ohya O, Sasaki H, Nagatani Y, Hayashi Y, Nomoto K: Therapeutic effect of SSM on hematological and immunological damage in X-ray irradiated mice. Clin Report 1990; 24: 441–448
Sasaki H, Schmitt DA, Kobayashi M, Hayashi Y, Pollard RB, Suzuki F: Prolongation of concomitant antitumor immunity in mice treated with Z-100, an arabinomannan extracted fromMycobacterium tuberculosis. Nat Immun 1993; 12: 152–167
Barker CC, Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983; 94: 331–335
Suzuki F, Pollard RB: Suppressor Lyt 2+ T- cells demonstrated in mice late after thermal injury. Immunol Lett 1988; 19: 33–40
Yokota Y: Host defense mechanism in experimentally immunocompromised animals and restorative effect of immunopotentiators. Jpn J Bacteriol 1984; 39: 29–45
Moss NM, Gough DB, Jordan AL, Grbic JT, Wood JJ, Rodrick ML, Mannick JA: Temporal correlation of impaired immune response after thermal injury with susceptibility to infection in a murine model. Surgery 1988; 104: 882–887
Kupper TS, Baker CC, Ferguson TA, Green DR: A burn induced Ly-2 suppressor T cell lowers resistance to bacterial infection. J Surg Res 1985; 38: 606–612
Kawamura I, Mitsuyama M, Nomoto K: Enhanced protection of cyclophosphamide-treated mice against infection withPseudomonas aeruginosa after treatment with Z-100, a polysaccharide-rich extract fromMycobacterium tuberculosis Aoyama B. Immunopharm and Immunotoxicol 1990; 12: 331–343
Kobayashi M, Herndon DN, Pollard RB and Suzuki F: Z-100, a lipid-arabinomannan extracted fromMycobacterium tuberculosis, improves the resistance of thermally injured mice to herpes virus infections. Immunology Lett 1994; 40: 199–205.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sasaki, H., Kobayashi, M., Emori, Y. et al. Z-100, a polysaccharide-rich preparation extracted from the human typeMycobacterium tuberculosis, improves the resistance of Meth-A tumor-bearing mice to endogenous septic infection. Biotherapy 10, 139–143 (1997). https://doi.org/10.1007/BF02678541
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02678541